拉泽替尼对比吉非替尼在EGFR突变晚期非小细胞肺癌中的中枢神经系统结局:LASER301亚组分析
LASER301亚组分析纳入86例基线中枢神经系统转移的EGFR突变晚期非小细胞肺癌患者,拉泽替尼组45例、吉非替尼组41例。拉泽替尼组中位颅内无进展生存期28.2个月,吉非替尼组8.4个月,风险比0.42(95%CI 0.20-0.89,p=0.02)。拉泽替尼组颅内客观缓解率94%(17例),吉非替尼组73%(11例,p=0.124)。
要点
- 拉泽替尼组中位颅内无进展生存期28.2个月,吉非替尼组8.4个月,HR 0.42,p=0.02。
- 可测量颅内病灶患者中,拉泽替尼组颅内客观缓解率94%(17例),吉非替尼组73%(11例,p=0.124)。
- 拉泽替尼组中位颅内缓解持续时间未达到(8.3-未达到),吉非替尼组6.3个月(2.8-未达到)。
核心结论
- 在基线中枢神经系统转移的EGFR突变晚期非小细胞肺癌患者中,拉泽替尼较吉非替尼显著改善颅内无进展生存期,且缓解更持久。
研究设计与样本
- LASER301是一项3期研究(ClinicalTrials.gov标识符NCT04248829),治疗初治的EGFR突变晚期非小细胞肺癌患者按1:1随机接受拉泽替尼240 mg/d或吉非替尼250 mg/d。
- 无症状或稳定的中枢神经系统转移患者纳入研究,前提是随机化前2周以上已完成任何计划的放疗、手术或类固醇治疗。
- 在筛选时确认或随后怀疑中枢神经系统转移的患者,每6周进行中枢神经系统影像学检查,持续18个月,之后每12周一次。
- 终点由盲法独立中心审查和实体瘤疗效评价标准1.1版评估,包括颅内无进展生存期、颅内客观缓解率和颅内缓解持续时间。
- LASER301共入组393例患者,其中86例(拉泽替尼组45例,吉非替尼组41例)有可测量和或不可测量的基线中枢神经系统转移。
主要发现
- 拉泽替尼组中位颅内无进展生存期为28.2个月(95%置信区间[CI]:14.8-28.2),吉非替尼组为8.4个月(95%CI:6.7-未达到[NR]),风险比=0.42,95%CI:0.20-0.89,p=0.02。
- 在可测量中枢神经系统病灶患者中,拉泽替尼组颅内客观缓解率为94%(17例),吉非替尼组为73%(11例,p=0.124),拉泽替尼组数值上更高。
- 拉泽替尼组中位颅内缓解持续时间为未达到(8.3-未达到),吉非替尼组为6.3个月(2.8-未达到)。
- 耐受性与LASER301总体人群相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lazertinib, a third-generation mutant-selective EGFR tyrosine kinase inhibitor, improved progression-free survival compared with gefitinib in the phase 3 LASER301 study (ClinicalTrials.gov Identifier: NCT04248829). Here, we report the efficacy of lazertinib and gefitinib in patients with baseline central nervous system (CNS) metastases. METHODS: Treatment-naive patients with EGFR-mutated advanced NSCLC were randomized one-to-one to lazertinib (240 mg/d) or gefitinib (250 mg/d). Patients with asymptomatic or stable CNS metastases were included if any planned radiation, surgery, or steroids were completed more than 2 weeks before randomization. For patients with CNS metastases confirmed at screening or subsequently suspected, CNS imaging was performed every 6 weeks for 18 months, then every 12 weeks. End points assessed by blinded independent central review and Response Evaluation Criteria in Solid Tumors version 1.1 included intracranial progression-free survival, intracranial objective response rate, and intracranial duration of response. RESULTS: Of the 393 patients enrolled in LASER301, 86 (lazertinib, n = 45; gefitinib, n = 41) had measurable and or non-measurable baseline CNS metastases. The median intracranial progression-free survival in the lazertinib group was 28.2 months (95% confidence interval [CI]: 14.8-28.2) versus 8.4 months (95% CI: 6.7-not reached [NR]) in the gefitinib group (hazard ratio = 0.42, 95% CI: 0.20-0.89, p = 0.02). Among patients with measurable CNS lesions, the intracranial objective response rate was numerically higher with lazertinib (94%; n = 17) versus gefitinib (73%; n = 11, p = 0.124). The median intracranial duration of response with lazertinib was NR (8.3-NR) versus 6.3 months (2.8-NR) with gefitinib. Tolerability was similar to the overall LASER301 population. CONCLUSIONS: In patients with CNS metastases, lazertinib significantly improved intracranial progression-free survival compared with gefitinib, with more durable responses.
引用
- Soo RA, Cho BC, Kim JH, et al. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis. J Thorac Oncol. 2023. PMID: 37865896. doi:10.1016/j.jtho.2023.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。